We also further explored the prognostic value of MET amplification in the TCGA database and the ctDNA of AGC patients, Kaplan–Meier survival curves showed that OS and DFS/PFS of GC patients with MET amplification was shorter than the patients with MET without amplification (P < 0.001 and P = 0.0078). The gene discussed is MET; the disease is gastric cancer.